Cargando…

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

INTRODUCTION: BAY 94-9027 is a newly developed extended half-life product to treat haemophilia, allowing for fewer injections than with standard products. This post hoc analysis aimed to compare physicians’ and patients’ opinions on BAY 94-9027 prophylaxis, and explore how qualitative interview data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lalezari, Shadan, Acquadro, Michaël, de Bock, Elodie, Lambert, Jérémy, Simpson, Mindy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467448/ https://www.ncbi.nlm.nih.gov/pubmed/32410165 http://dx.doi.org/10.1007/s12325-020-01374-2

Ejemplares similares

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
por: Reding, Mark T., et al.
Publicado: (2021)

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
por: Lalezari, Shadan, et al.
Publicado: (2019)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
por: Hakimi, Zalmai, et al.
Publicado: (2020)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
por: Wells, Jane R., et al.
Publicado: (2019)

Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG
por: Ivens, Inge A., et al.
Publicado: (2019)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
por: Solms, Alexander, et al.
Publicado: (2019)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Haemophilia A and B – evaluation of the Swedish prophylactic regimen by magnetic resonance imaging
por: Lundin, Björn, et al.
Publicado: (2022)

Motivation of Physicians to Use and Recommend Apps for the Treatment of Haemophilia
por: Alpar, Paul, et al.
Publicado: (2021)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Draft Genome Sequence of Pseudomonas aeruginosa ATCC 9027, Originally Isolated from an Outer Ear Infection
por: Jayal, Ambikesh, et al.
Publicado: (2017)

UK vs US physician decision‐making in the treatment of haemophilia
por: Lamb, Christopher C., et al.
Publicado: (2019)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Pain and pain management in haemophilia
por: Auerswald, Günter, et al.
Publicado: (2016)

Barriers to prophylactic treatment among patients with haemophilia A in Shandong Province, China: a qualitative study
por: Liu, Ziyu, et al.
Publicado: (2023)

How to discuss gene therapy for haemophilia? A patient and physician perspective
por: Miesbach, Wolfgang, et al.
Publicado: (2019)

Perioperative, Functional, and Oncologic Outcomes of On-Clamp Versus Off-Clamp Partial Nephrectomy: An Updated Meta-analysis of 9027 Patients
por: Serag, Hosam, et al.
Publicado: (2023)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

Legg on Hæmophilia
Publicado: (1873)

Malarious Hæmophilia
Publicado: (1890)

The Treatment of Haemophilia
por: Biggs, Rosemary
Publicado: (1969)

Living with Haemophilia
por: Laffan, Mike
Publicado: (1995)

Draft Genome Sequence of Pseudomonas aeruginosa ATCC 9027 (DSM 1128), an Important Rhamnolipid Surfactant Producer and Sterility Testing Strain
por: Mai-Prochnow, Anne, et al.
Publicado: (2015)

Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment
por: Petrova, Guenka, et al.
Publicado: (2014)

Newborn screening for haemophilia: The views of families and adults living with haemophilia in the UK
por: Boardman, Felicity K., et al.
Publicado: (2019)

Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines
por: Petkovic, Madison J., et al.
Publicado: (2022)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Hæmophilia in Northern Ireland
por: Nelson, M. G., et al.
Publicado: (1959)

Dental Treatment in Hæmophilia
por: Nicholl, B., et al.
Publicado: (1959)

Cannot write session to /tmp/vufind_sessions/sess_n73hh0jjihsh62lp34mdhru71d